Responses to Requests for Proposals
Forecasted
Responses to Requests for Proposals supports organizations delivering independent education for healthcare professionals and patients to address knowledge gaps and improve care in ATTR amyloidosis, AHP, and PH1.
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): October 2027 (Submission deadline)
Funding Amounts: Earlier ATTR implementation RFP: up to $150,000 USD per request
Summary: Supports independent medical education addressing knowledge gaps and patient care in ATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1.
Key Information: Only organizations or entities may apply; valid, government-issued proof of tax status is required.
Description
Alnylam Pharmaceuticals’ Grants and Giving Office posts Requests for Proposals inviting organizations and qualified medical education providers to develop independent educational initiatives. The program supports evidence-based, clinically relevant, performance-based education for healthcare professionals and patients, addressing educational gaps, unmet needs, standards of care, ongoing research, and community needs.
Activities must align with the relevant RFP and Alnylam’s disease areas: transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Grantees independently design and execute their initiatives. Alnylam may not receive a tangible business benefit, and transparent acknowledgment of its support is required. This RFP process is separate from the investigator-initiated studies pathway.
